Peptides for eczema, psoriasis, and chronic skin conditions

Chronic is not the same as untreatable. But it does mean that the model of skin disease you probably started with — something goes wrong, you treat it, it goes away — needs to be replaced with a more complicated one. Atopic dermatitis, psoriasis, hidradenitis suppurativa, chronic urticaria, and the broader spectrum of immune-mediated skin disease are not primarily surface problems. They are system problems that express themselves on the surface. The skin is the readout. The biology behind it runs deeper.

Understanding that biology is where the leverage is.

Atopic dermatitis — the clinical name for eczema — involves two converging failures. The first is a barrier problem. Healthy skin maintains a tightly packed outer layer, the stratum corneum, held together in part by a structural protein called filaggrin. In many people with eczema, filaggrin is deficient — either from genetic variants in the FLG gene, or from the effects of inflammation itself damaging the cells that make it. A compromised filaggrin layer means the skin's waterproofing is incomplete. Moisture escapes. Allergens and microbes that should stay outside penetrate inward. The immune system in the dermis encounters things it wasn't supposed to encounter, and it reacts. The itch-scratch cycle is partly a consequence of that reaction and partly its amplification, because scratching further damages the barrier that's already failing.

The second failure is immune dysregulation. In eczema, the dominant immune pattern is Th2 — a branch of the adaptive immune system that drives type 2 inflammation, characterized by high IL-4, IL-13, and IL-31 signaling. IL-31 is directly involved in itch signaling to the nervous system, which explains why eczema itches the way it does: it's not surface irritation, it's a cytokine talking directly to nerves. The Th2 skew also suppresses aspects of innate immune defense, including the production of antimicrobial peptides. One antimicrobial peptide particularly affected is LL-37, a member of the cathelicidin family, which healthy skin produces robustly as a first-line defense against bacteria, viruses, and fungi. In eczema, LL-37 levels are paradoxically low. This is one reason Staphylococcus aureus colonization on eczematous skin is so common and so consequential — the antimicrobial barrier is down, and staph colonization further amplifies the Th2 inflammatory response, driving the cycle harder.

Psoriasis is a different immune story. Where eczema runs predominantly Th2, psoriasis is driven by Th17 and Th22 pathways — a pattern that produces high IL-17 and IL-22 signaling. IL-17 drives keratinocyte proliferation, which is why psoriatic skin accumulates in the thick, scaly plaques characteristic of the disease. The skin is turning over far too fast, producing cells faster than they can mature and shed properly. The inflammatory infiltrate in psoriatic plaques is dense with neutrophils and T cells. The condition has a significant systemic dimension: psoriatic arthritis affects a meaningful subset of people with psoriasis, and psoriasis is associated with elevated cardiovascular risk, likely through shared inflammatory mechanisms. It's not just skin.

Hidradenitis suppurativa affects hair follicles in areas where skin folds — the axillae, groin, inframammary folds — and involves a complex interplay of follicular occlusion, inflammatory rupture, and chronic wound formation. Chronic urticaria — hives that persist beyond six weeks — often involves mast cell hyperreactivity, with IgE-mediated and non-IgE-mediated triggers, and a substantial subset has no identifiable cause. The microbiome threads through all of these: disruption of the skin microbiome affects barrier function, immune education, and the local inflammatory environment. The gut-skin axis is a related concept — gut dysbiosis appears to influence systemic immune tone in ways that surface on the skin, though the precise mechanisms are still being worked out.

The conventional dermatology hierarchy for these conditions has changed substantially in the last decade, and that change matters for how to think about adjunctive approaches.

For eczema, the foundation is consistent moisturization — not optional, not just when it's bad, but daily, the way a person with dry eyes uses eye drops. Topical corticosteroids remain the workhorse for acute flares, and their appropriate use is not a risk when used correctly; the fear of steroid phobia has led to undertreatment in many patients. Calcineurin inhibitors — tacrolimus and pimecrolimus — offer a steroid-sparing option for sensitive areas. Topical PDE4 inhibitors like crisaborole add another non-steroidal tier. Then there are the biologics. Dupilumab, which blocks IL-4 and IL-13 signaling simultaneously, has genuinely transformed care for moderate-to-severe atopic dermatitis. For many patients who suffered for years with inadequate control, dupilumab represented a category shift. Tralokinumab and lebrikizumab, targeting IL-13 specifically, extend the biologic options. JAK inhibitors — upadacitinib and abrocitinib orally, ruxolitinib topically — offer a newer mechanistic approach that works downstream in the inflammatory cascade.

For psoriasis, the biologic era has been equally significant. Drugs targeting IL-17 (secukinumab, ixekizumab, bimekizumab), IL-23 (guselkumab, risankizumab, tildrakizumab), and TNF (the older agents) have shifted the treatment ceiling dramatically. Clearance that wasn't achievable with older therapies is now routine for the right patient on the right biologic. For chronic urticaria, omalizumab — an anti-IgE antibody — has changed the picture for patients who don't respond adequately to antihistamines.

Against that backdrop, where do peptides enter?

They enter carefully, and in a supporting role. The honest framing is that no peptide replaces a biologic for moderate-to-severe eczema or psoriasis. The evidence base for biologics in these conditions is robust, the clinical outcomes are substantial, and the mechanism is specific and verified. Peptides, by contrast, are at best adjunctive — potentially useful for the inflammatory and barrier components, but not substitutes for the established hierarchy.

GHK-Cu, a copper tripeptide with a long history in wound healing research, has been studied for its effects on skin barrier support and its anti-inflammatory properties. Topically, it appears to influence fibroblast activity, collagen synthesis, and the regulation of inflammatory signaling through effects on transcription factors including NF-kB. In the eczema context, this means potential support for the barrier repair side of the equation — the filaggrin-adjacent work of reinforcing skin structural integrity. The evidence is primarily in vitro and in smaller human studies, not in large randomized controlled trials comparing it to standard-of-care treatments. But the mechanism is coherent, the safety profile of topical copper peptides is well-characterized, and some dermatology researchers view it as a reasonable adjunct to barrier support regimens.

KPV is a tripeptide — lysine-proline-valine — derived from alpha-MSH and researched for its anti-inflammatory properties. It appears to act through melanocortin receptors and through direct effects on inflammatory cytokine signaling, including IL-6 and TNF-alpha. In preclinical and early research, it has shown anti-inflammatory activity in gut mucosa and skin contexts. The inflammatory component of both eczema and psoriasis makes it a conceptually relevant target, though clinical evidence in human dermatological conditions remains limited.

VIP — vasoactive intestinal peptide — is a neuropeptide with broad immunomodulatory properties. It shifts the immune system toward anti-inflammatory signaling, suppresses Th1 and Th17 responses, and promotes regulatory T cell activity. Because the Th17 axis is central to psoriasis pathophysiology, there is theoretical interest in VIP as a modulator in that context. This remains primarily at the research stage; systemic VIP approaches in dermatological disease have not been clinically validated at scale.

Thymosin Alpha-1, researched primarily for its immunoregulatory effects in viral hepatitis and immune-compromised states, has some interest in the context of conditions where immune dysregulation is prominent. The logic in immune-mediated skin disease is the normalization hypothesis — that broad immune system balance may reduce the hyperreactive patterns driving disease. The evidence for this specific application is indirect, and your prescribing provider would need to evaluate whether this has a place in an individual protocol.

The LL-37 angle is worth dwelling on, because it illustrates how the peptide picture in inflammatory skin disease is genuinely not simple. LL-37 is endogenously low in eczema, and the consequences of that deficiency are real — Staph aureus colonization, impaired viral defense, a partially disabled innate immune layer. Yet LL-37 is elevated in psoriasis, where it appears to contribute to the inflammatory amplification characteristic of the disease. Topical approaches to raise LL-37-like activity in eczema have been researched in preclinical contexts. But the directional relationship is opposite in psoriasis. This is a good example of why the peptide landscape in inflammatory skin disease cannot be approached with a single intervention in mind — the biology of different conditions, and even the biology of the same skin in different areas, runs in different directions.

The gut-skin connection deserves specific acknowledgment because it changes what foundational work looks like. If gut dysbiosis is contributing to systemic immune tone that surfaces on the skin, then addressing gut health — through dietary changes, probiotic approaches, and sometimes gut-specific peptides like BPC-157 researched for gut mucosal support — becomes part of the skin picture. This is not a replacement for dermatology treatment, but it's a reason why the skin often improves when other parts of the system settle down.

Trigger identification matters enormously and is often underdone. In eczema, contact allergens, aeroallergens, food sensitivities (particularly in pediatric disease), environmental factors, stress (which directly upregulates Th2 signaling via cortisol), and sweat all contribute in different proportions for different people. In psoriasis, stress, streptococcal infections, certain medications (lithium, beta-blockers, antimalarials), and alcohol are established triggers. The time spent identifying your specific trigger landscape is not wasted time — it is often the most direct route to reducing flare frequency.

The foundational interventions work whether or not anything else does. Consistent, appropriate moisturization with a fragrance-free emollient, applied immediately after bathing while the skin is still slightly damp. Avoidance of identified triggers. Temperature control (eczema particularly hates overheating). Adequate sleep, which directly affects immune regulation. Sometimes dietary trials — the evidence for specific diets in inflammatory skin conditions is limited but individual variation is real, and a short exclusion trial supervised by a knowledgeable provider can be informative. Stress management, not as a soft suggestion but because HPA axis activity and Th2 skewing are directly connected.

If you have moderate-to-severe eczema or psoriasis and you have not had a thorough conversation with a dermatologist about the biologic options, that conversation is worth having before exploring adjunctive peptide approaches. The transformation that dupilumab has produced for eczema, and that IL-17 and IL-23 inhibitors have produced for psoriasis, is documented at scale. Peptides are at best adjunctive to that tier of care, not an alternative to it. For milder disease, for the barrier support component, for people exploring the gut-skin and immune balance dimensions alongside standard care — that's where the peptide conversation begins to make sense, and where a prescribing provider with dermatology awareness can help you assess what's reasonable for your specific presentation.

Chronic skin disease carries a particular weight that is hard to explain to people who haven't had it. The visibility of it, the unpredictability of it, the accumulation of interventions that helped partially but not enough. The mechanisms are increasingly well understood. The tools are genuinely better than they were a decade ago. And the question of what adjunctive biology might further support the system — the barrier, the immune balance, the gut connection — is a real and reasonable question to bring into a careful clinical conversation.